Highlights
- An accredited education platform has been launched for British healthcare professionals at no cost to users.
- The group’s UK laboratory arm has introduced manufacturing of new medical cannabis delivery formats domestically.
- A certified liquid inhalation device has been brought to the British prescription market.
Curaleaf Holdings
(TSX:CURA)
Curaleaf Holdings Inc. (TSX:CURA)
13.40
CAD
-0.050
0.372%
Last Updated at: 2026-08-31T20:00:00Z
, through its international arm, has built one of the more substantial commercial positions in British medical cannabis, and its recent activity has centred on an unusual target: not patients, and not prescriptions, but the clinicians who write them. The approach reflects a diagnosis of where the UK market is actually constrained.
The Bottleneck Is Knowledge, Not Demand
Britain’s medical cannabis framework allows specialist clinicians to prescribe cannabis-based products for medicinal use, yet uptake within the state system has remained narrow while the private clinic sector has expanded. A recurring explanation from within the industry is that most clinicians received no training in cannabinoid medicine and are understandably reluctant to prescribe outside their competence.
That is a training problem rather than a demand problem, and it is one that marketing cannot fix.
An Accredited Platform
The group’s response has been to launch an education platform providing accredited medical cannabis training programmes for healthcare professionals across the United Kingdom, offered free at the point of registration and structured to progress from introductory through to advanced levels.
Continuing professional development accreditation matters because it means the learning counts towards the requirements clinicians must meet anyway. That converts the offering from a promotional resource into a professionally useful one, which is a materially different value proposition.
The group has also partnered with a clinicians’ society focused on the same educational gap, reinforcing the strategy through established professional networks.
Manufacturing And Delivery Formats
On the product side, the group’s British laboratory operation reported becoming the first licensed manufacturer in the country to develop and produce medical cannabis suppositories and pessaries, formats intended for patients unable to benefit from conventional routes of administration.
It has separately launched a certified liquid inhalation device available on prescription in Britain, addressing another delivery route within a regulated medical device framework.
Both moves point to the same commercial insight: differentiation in medical cannabis increasingly comes from formulation and delivery rather than from the plant material itself.
Domestic Manufacture, International Ownership
The group carries out pharmaceutical-grade manufacturing in Britain, imports bulk material for oil production and completes final packaging domestically for imported flower. That arrangement gives it a genuine UK industrial footprint while remaining part of an internationally listed structure.
It also underlines a point UK investors keep encountering. The most developed British medical cannabis businesses are subsidiaries of companies quoted elsewhere, which is why exposure to the domestic patient base is not readily available on the London board.
The Policy Question Hanging Over It
A formal review of the regulation of cannabis-based products for medicinal use has been commissioned through the relevant advisory council, examining whether the original framework has delivered its intended outcomes. Any resulting change to prescribing guidance or state commissioning would alter the commercial landscape considerably.
Building clinician familiarity ahead of such a review is, at minimum, a well-timed piece of positioning.
